Delivery Order SPE2DB20D3103-SPE2DB25FP6W2
- Not listed
- The Defense Logistics Agency awarded a $7,733.54 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 1 mg on September 22, 2025, with completion scheduled for October 14, 2025. This non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,503.86. This competitively awarded, non-set-aside contract was executed on November 4, 2025, with an ultimate completion date of November 26, 2025. The firm fixed price delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, supporting federal pharmaceutical supply requirements. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,718.48 to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 1 mg on August 4, 2025, with an ultimate completion date of August 25, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery...
- The Defense Logistics Agency has awarded a delivery order valued at $1,711.95 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 4 mg tablets (100-count packaging). This firm fixed-price delivery order was competitively awarded without set-aside provisions and is scheduled for completion by October 21, 2025. The contract will be performed at the awardee's corporate headquarters in Conshohocken, Pennsylvania, where AmerisourceBergen maintains operations as a primary pharmaceutical...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Envarsus XR 1 mg tablets (30-count packages) with a ceiling value of $1,553.40. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 4, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Envarsus XR 1 mg tablets (30-count units) valued at $1,035.60. This non-competitive delivery order, which will be completed by June 24, 2025, represents a firm fixed-price transaction issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contractor, headquartered in Conshohocken, Pennsylvania, will perform this delivery...
- The Defense Logistics Agency awarded a $6,847.80 delivery order to AmerisourceBergen Drug Corp for Envarsus XR 4 mg tablets (100-count units) on May 5, 2025, with completion targeted for May 27, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The vendor, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (30-count units) under a firm fixed-price contract valued at $1,165.05. The award was made on September 22, 2025, with an ultimate completion date of October 14, 2025. This delivery order represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $1,711.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units). This is a non-set-aside competitive award with an ultimate completion date of September 4, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $1,811.00 to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 1 mg on October 29, 2025, with completion targeted for November 20, 2025. This firm fixed-price contract, issued without a set-aside designation, represents a competitively awarded order for a specialized immunosuppressant medication. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP6W2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,165.05 to AmerisourceBergen Drug Corp for 30 tablets of Envarsus XR 1 mg on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order carries no set-aside designation and represents a competitively awarded transaction under the company's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's comprehensive IDC with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract vehicle functions as a global pharmaceutical support mechanism enabling the company to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. Envarsus XR, an immunosuppressant medication, represents one of the specialized pharmaceutical products the contractor delivers through its extensive federal contract portfolio supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 7/29/25 |